血清NT—proBNP和PCT的检测在慢性心力衰竭患者中的临床意义(1)

http://www.100md.com 2018年3月25日 《中外医疗》 20189

     [摘要] 目的 探討N末端脑钠肽前体(NT-proBNP)和降钙素原(PCT)的检测在心力衰竭(HF)患者中的临床意义。 方法 方便选取2016年5月—2017年5月该院心内科住院的110例HF不同心功能分级患者(实验组)及85名健康查体者(对照组)，分别检测两组血清中的NT-proBNP和PCT含量以及心脏彩超指标，并检测实验组患者治疗后的上述指标变化状况。 结果 ①实验组的NT-proBNP水平(2 356.4±236.9)pg/mL、PCT(1.153±0.264)ng/mL、LVEDD(58.2±5.1)mm、LVEF(38.1±3.3)%，均显著高于对照组差异有统计学意义(P<0.05)，且心功能越差，患者NT-proBNP、PCT水平浓度越高(F=596.042、113.58，P<0.05)；②经有效治疗后，心功能Ⅱ级患者的NT-proBNP(127.6±21.5)pg/mL、PCT(0.247±0.092)ng/mL，心功能Ⅲ级的NT-proBNP(364.3±86.1)pg/mL、PCT(0.414±0.125)ng/mL，心功能Ⅳ级的NT-proBNP为(708.6±198.4)pg/mL、PCT(0.637±0.362)ng/mL，均显著低于治疗前水平(P<0.05)。 结论 NT-proBNP和PCT的检测能更好的反应HF患者的严重程度及治疗效果，对HF患者有极重要的临床意义。

    [关键词] B型脑钠肽；降钙素原；慢性心力衰竭

    [中图分类号] R4 [文献标识码] A [文章编号] 1674-0742(2018)03(c)-0008-03

    Clinical Significance of Serum NT-proBNP and PCT Test in Patients with Chronic Heart Failure

    WANG Yun-feng

    Department of Clinical Laboratory， Chengyang District People’s Hospital， Qingdao， Shandong Province， 266109 China

    [Abstract] Objective To study the clinical significance of serum NT-proBNP and PCT test in patients with chronic heart failure. Methods 110 cases of patients with different cardiac function classifications in our hospital from May 2016 to May 2017 were convenient selected as the experimental group， and 85 cases of healthy physical examination people were selected as the control group， and the NT-proBNP and PCT constant and cardiac color ultrasound indicators of the two groups were respectively tested， and the changes of the above indicators in the experimental group after treatment was tested. Results ①The NT-proBNP， PCT， LVEDD， LVEF in the experimental group were respectively (2 356.4±236.9)pg/mL，(1.153±0.264)ng/mL， (58.2±5.1)mm， (38.1±3.3)%， which were obviously higher than those in the control group(P<0.05)， the worse the cardiac function， the higher the concentrations of NT-proBNP and PCT levels(F=596.042，113.58，P<0.05)； ②after the effective treatment， the NT-proBNP and PCT of patients with level-Ⅱ cardiac function， level-Ⅲ cardiac function and level-Ⅳ cardiac function were respectively (127.6±21.5)pg/mL， (0.247±0.092)ng/ml， (364.3±86.1)pg/mL， (0.414±0.125)ng/mL， (708.6±198.4)pg/mL， (0.637±0.362)ng/mL， which were obviously lower than those before treatment the difference was statistically significant(P<0.05). Conclusion The test of NT-proBNP and PCT can better reflect the severity of HF patients and treatment effect， which is of very important significance to the HF patients.

    [Key words] B-type natriuretic peptide； PCT； Chronic heart failure, 百拇医药(王云峰)

第 1 2 页 下一页

    百拇医药网 http://www.100md.com/html/paper/1674-0742/2018/09/03.htm